Dr. Scott Waldman, MD

• Pharmacology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Stanford

  Residency Hospital, 1990

• Stanford University

  Medical School, 1987

• GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer, 2014-09-08

• Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia, 2019-02-02

• TCR Retrogenic Mice as a Model to Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen Guanylyl Cyclase C (GUCY2C), 2019-01-14

• Occult Tumor Burden Contributes to Racial Disparities in Stage-Specific Colorectal Cancer Outcomes, 2011-09-01

• A Novel CDX2 Isoform Regulates Alternative Splicing, 2014-08-07

• Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity, 2010-09-01

• Guanylyl cyclase C -induced immunotherapeutic responses opposing tumor metastases without autoimmunity, 2008-06-24

• Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics, 2010-08-05

• Intestinal GUCY2C Prevents TGF-ß Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer, 2013-10-01

• Bioactivity of oral linaclotide in human colorectum for cancer chemoprevention, 2017-04-10

• Tumor Radiotherapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C, 2014-04-01

• Regulation of appetite to treat obesity, 2011-03-01

• Mechanisms of Weight Regain following Weight Loss, 2013-04-16

• GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer, 2013-11-07

• Guanylyl Cyclase C Is a Specific Marker for Differentiating Primary and Metastatic Ovarian Mucinous Neoplasms, 2011-07-06

• Stem cells as therapeutic targets in colorectal cancer, 2021-02-10

• GUCY2C molecular staging personalizes colorectal cancer patient management, 2012-09-10

• Expression of the Intestinal Biomarkers Guanylyl Cyclase C and CDX2 in Poorly Differentiated Colorectal Carcinomas, 2009-10-01

• Previstage™ GCC test for staging patients with colorectal cancer, 2010-01-28

• An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer, 2020-10-06

• A study of micro RNAs in silico and in vivo: Diagnostic and therapeutic applications in cancer, 2009-02-25

• The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge towards complete remission, 2021-05-24

• Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High Avidity Effector CD8+T Cells, 2017-03-24

• Taking a lesson from microbial diarrheagenesis in the management of chronic constipation, 2010-01-27

• Guanylyl Cyclase C Prevents Colon Cancer Metastasis by Regulating Tumor Epithelial Cell Matrix Metalloproteinase 9, 2009-03-31

• A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients, 2016-10-03

• T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C, 2022-03-09

• Plp1gene duplication inhibits airway responsiveness and induces lung inflammation, 2014-11-04

• Association of GUCY2C Expression in Lymph Nodes and Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer, 2009-02-18

• The Transcription Factor Encyclopedia, 2012-03-29

• Selection of optimal reference genes for normalization in quantitative RT-PCR, 2010-05-14

• Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy, 2022-06-23

• CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-cell Acute Lymphoblastic Leukemia, 2015-05-04

• Sizing Up Pharmacotherapy for Obesity, 2010-04-20

• Emerging drug targets for colon cancer: A preclinical assessment, 2022-02-10

• Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications Bamberg, Germany. 23-25 June, 2017, 2017-10-10

• Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases, 2018-04-03

• A Conserved Tissue-Specific Homeodomain-Less Isoform of MEIS1 Is Downregulated in Colorectal Cancer, 2011-08-17

• ST-ProducingE. coliOppose Carcinogen-Induced Colorectal Tumorigenesis in Mice, 2017-09-12

• Phosphorylation of Vasodilator-Stimulated Phosphoprotein Ser239 Suppresses Filopodia and Invadopodia in Colon Cancer, 2011-08-12

• Obesity pharmacotherapy: What is next?, 2012-10-24

• Cytokine Adjuvanation of Therapeutic Anti-Tumor Immunity Targeted to Cancer Mucosa Antigens, 2008-11-13

• Clinical pharmacology at the core of translational science, 2020-01-13

• Intestinal neuropod cell GUCY2C regulates visceral pain, 2023-02-15

• Synergistic DNA-adenovirus prime-boost immunization eliminates metastatic colorectal cancer by inducing high avidity effector CD8+ T cells, 2014-11-06

• Hormone suppression silencing GUCY2C is required for colorectal cancer, 2015-09-02

• Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients, 2019-04-23

• The Value Proposition of Molecular Medicine, 2012-02-23

• Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer, 2011-02-09

• Ferid Murad, MD, PhD at 80: A Legacy of Science, Medicine, and Mentorship, 2018-01-02

• GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients, 2010-01-12

• Lineage-specific T cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease, 2009-04-07

• MOLECULAR STAGING ESTIMATES OCCULT TUMOR BURDEN IN COLORECTAL CANCER, 2020-02-03

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer, 2021-02-02

• The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer, 2014-10-10

• The orl rat is more responsive to methacholine challenge than wild type, 2014-09-16

• Modeling qRT-PCR dynamics with application to cancer biomarker quantification, 2017-05-14

• Analytic Lymph Node Number Establishes Staging Accuracy by Occult Tumor Burden in Colorectal Cancer, 2012-01-17

• Healthcare Evolves From Reactive to Proactive, 2018-11-16

• GUCY2C maintains intestinal LGR5+stem cells by opposing ER stress, 2017-10-26

• Companion diagnostics at the intersection of personalized medicine and healthcare delivery, 2017-06-15

• Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis, 2016-01-15

• GUCY2C signaling opposes the acute radiation-induced GI syndrome, 2017-09-15

• Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy, 2010-05-05

• The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling, 2009-09-06

• Guanylate Cyclase C as a Target for Prevention, Detection, and Therapy in Colorectal Cancer, 2017-04-10

• GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity, 2012-02-22

• GUCY2C at the intersection of obesity and colorectal cancer, 2013-08-29

• Dexamethasone-loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhances Therapeutic Efficacy:A Novel Application in Pediatric Nanomedicine, 2012-11-29

• Guanylyl cyclase C as a biomarker in colorectal cancer, 2013-03-29